Twelve-month kinetics of circulating fibrosis-linked microRNAs (miR-21, miR-29, miR-30, and miR-133a) and the relationship with extracellular matrix fibrosis in dilated cardiomyopathy

Paweł Rubiś; Justyna Totoń-Żurańska; Maria Kołton-Wróż; Paweł Wołkow; Ewelina Pitera; Sylwia Wiśniowska-Śmiałek; Ewa Dziewięcka; Ann Garlitski; Piotr Podolec

doi:10.5114/aoms.2019.89777

Twelve-month kinetics of circulating fibrosis-linked microRNAs (miR-21, miR-29, miR-30, and miR-133a) and the relationship with extracellular matrix fibrosis in dilated cardiomyopathy

Arch Med Sci. 2019 Nov 18;18(2):480-488. doi: 10.5114/aoms.2019.89777. eCollection 2022.

Authors

Paweł Rubiś¹, Justyna Totoń-Żurańska², Maria Kołton-Wróż², Paweł Wołkow², Ewelina Pitera², Sylwia Wiśniowska-Śmiałek¹, Ewa Dziewięcka¹, Ann Garlitski³, Piotr Podolec¹

Affiliations

¹ Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland.
² Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Krakow, Poland.
³ Tufts Medical Center Boston, Massachusetts, USA.

Abstract

Introduction: A single measurement of any biomarker may not reflect its full biological meaning. The kinetics of fibrosis-linked microRNAs and their relationship with extracellular matrix (ECM) fibrosis in dilated cardiomyopathy (DCM) have not been explored.

Material and methods: We evaluated 70 consecutive DCM patients (48 ±12.1 years, left ventricular ejection fraction 24.4 ±7.4%). All patients underwent right ventricular endomyocardial biopsy in order to quantify ECM fibrosis and measure collagen volume fraction (CVF). Circulating microRNAs (miR-21-5p, miR-29b, miR-30c-5p, and miR-133a-3p) were measured with quantitative polymerase chain reaction (PCR) at baseline and at 3 and 12 months.

Results: Based on the biopsy results, two groups of patients were identified: with (n = 24, 34.3%) and without (n = 46, 65.7%) ECM fibrosis. Except for a single measurement of miR-29b at 3 months (DCM with fibrosis: 6.03 ±0.72 vs. DCM without fibrosis: 6.4 ±0.75 ΔCq; p < 0.05), baseline, 3- and 12-month kinetics of microRNAs did not differ between the two groups. Moreover, 12-month microRNA kinetics did not differ in patients with new-onset DCM (duration < 6 months; n = 35) and chronic DCM (> 6 months; n = 35). Only miR-29 at 3 months correlated with CVF (r = -0.31; p < 0.05), whereas other microRNAs did not correlate with CVF either at 3 or at 12 months.

Conclusions: Regardless of ECM fibrosis status or duration of the disease, 12-month patterns of circulating microRNAs are similar in DCM. Correlations between microRNAs, measured at 3 and 12 months, are lower than expected. In this study, regardless of the time point, circulating microRNAs were not able to differentiate between DCM patients with versus without fibrosis.

Keywords: cardiomyopathy; fibrosis; kinetics; microRNA.